{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T14:29:32Z","timestamp":1761920972256,"version":"3.40.4"},"reference-count":11,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"51","license":[{"start":{"date-parts":[[2021,12,23]],"date-time":"2021-12-23T00:00:00Z","timestamp":1640217600000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:sec>\n            <jats:title>Rationale:<\/jats:title>\n            <jats:p>Teriflunomide is an inhibitor of pyrimidine synthesis available as a first-line treatment for relapsing-remitting multiple sclerosis. Drug-induced liver damage is a relevant problem in clinical practice, representing a frequent cause of treatment discontinuation. This case report describes the occurrence of liver injury, with a 33.7-fold increase in the upper limit of normality of the liver enzyme alanine aminotransferase during treatment with teriflunomide 14\u200amg.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Patient concern:<\/jats:title>\n            <jats:p>A 44-year-old woman receiving teriflunomide 14\u200amg for the treatment of multiple sclerosis presented symptoms suggestive of liver dysfunction 54\u200adays after starting treatment. The patient had no history of using disease-modifying therapy, neither previous liver disease nor other comorbidities.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Diagnostics:<\/jats:title>\n            <jats:p>The suggested diagnosis was drug-induced liver injury, classified as hepatocellular. Other possible hepatic and autoimmune etiologies were ruled out.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Interventions:<\/jats:title>\n            <jats:p>Replacement of teriflunomide treatment with glatiramer acetate and follow-up of the disease.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Outcomes:<\/jats:title>\n            <jats:p>Signs and symptoms regressed after treatment with teriflunomide 14\u200amg was discontinued, with normalization of liver enzyme activity in \u223c5\u200amonths. The causality assessment of the adverse drug reaction was determined by the Naranjo scaling system, resulting in probable, with a final score of 7.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusions:<\/jats:title>\n            <jats:p>Teriflunomide-induced liver injury in patients with multiple sclerosis is a serious adverse reaction. The report of this case contributes to updating knowledge about the safety aspects of treatment with teriflunomide and planning of monitoring strategies and patient risk management.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/md.0000000000028246","type":"journal-article","created":{"date-parts":[[2021,12,23]],"date-time":"2021-12-23T14:29:47Z","timestamp":1640269787000},"page":"e28246","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":7,"title":["Hepatotoxicity associated with the use of teriflunomide in a patient with multiple sclerosis"],"prefix":"10.1097","volume":"100","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0438-047X","authenticated-orcid":false,"given":"Cristiane Munaretto","family":"Ferreira","sequence":"first","affiliation":[{"name":"Pharmacy Post-Graduation Program, Faculty Pharmaceutical Sciences, Food and Nutrition, Federal University of Mato Grosso do Sul, Campo Grande \u2013 MS, Brazil"},{"name":"Pharmacy School Prof\u00aa Ana Maria Cervantes Baraza, Faculty Pharmaceutical Sciences, Food and Nutrition, Federal University of Mato Grosso do Sul, Campo Grande \u2013 MS, Brazil"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Erica Freire de","family":"Vasconcelos-Pereira","sequence":"additional","affiliation":[{"name":"Pharmacy School Prof\u00aa Ana Maria Cervantes Baraza, Faculty Pharmaceutical Sciences, Food and Nutrition, Federal University of Mato Grosso do Sul, Campo Grande \u2013 MS, Brazil"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vanessa Marcon de","family":"Oliveira","sequence":"additional","affiliation":[{"name":"Pharmacy School Prof\u00aa Ana Maria Cervantes Baraza, Faculty Pharmaceutical Sciences, Food and Nutrition, Federal University of Mato Grosso do Sul, Campo Grande \u2013 MS, Brazil"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pedro Rippel","family":"Salgado","sequence":"additional","affiliation":[{"name":"Faculty of Medicine, Federal University of Mato Grosso do Sul, Campo Grande \u2013 MS, Brazil."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jo\u00e3o Am\u00e9rico","family":"Domingos","sequence":"additional","affiliation":[{"name":"Faculty of Medicine, Federal University of Mato Grosso do Sul, Campo Grande \u2013 MS, Brazil."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maria Tereza Ferreira Duenhas","family":"Monreal","sequence":"additional","affiliation":[{"name":"Pharmacy School Prof\u00aa Ana Maria Cervantes Baraza, Faculty Pharmaceutical Sciences, Food and Nutrition, Federal University of Mato Grosso do Sul, Campo Grande \u2013 MS, Brazil"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elvira Maria","family":"Guerra-Shinohara","sequence":"additional","affiliation":[{"name":"Pharmacy Post-Graduation Program, Faculty Pharmaceutical Sciences, Food and Nutrition, Federal University of Mato Grosso do Sul, Campo Grande \u2013 MS, Brazil"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vanessa Terezinha","family":"Gubert","sequence":"additional","affiliation":[{"name":"Pharmacy Post-Graduation Program, Faculty Pharmaceutical Sciences, Food and Nutrition, Federal University of Mato Grosso do Sul, Campo Grande \u2013 MS, Brazil"},{"name":"Pharmacy School Prof\u00aa Ana Maria Cervantes Baraza, Faculty Pharmaceutical Sciences, Food and Nutrition, Federal University of Mato Grosso do Sul, Campo Grande \u2013 MS, Brazil"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","published-online":{"date-parts":[[2021,12,23]]},"reference":[{"key":"R1-20250504","doi-asserted-by":"crossref","first-page":"1622","DOI":"10.1016\/S0140-6736(18)30481-1","article-title":"Multiple sclerosis","volume":"391","author":"Thompson","year":"2018","journal-title":"Lancet"},{"key":"R2-20250504","doi-asserted-by":"crossref","DOI":"10.1177\/1756286419836571","article-title":"Risks and risk management in modern multiple sclerosis immunotherapeutic treatment","volume":"12","author":"Klotz","year":"2019","journal-title":"Ther Adv Neurol Disord"},{"key":"R5-20250504","doi-asserted-by":"crossref","first-page":"1293","DOI":"10.1056\/NEJMoa1014656","article-title":"Randomized trial of oral teriflunomide for relapsing multiple sclerosis","volume":"365","author":"O\u2019Connor","year":"2011","journal-title":"N Engl J Med"},{"key":"R6-20250504","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1016\/S1474-4422(13)70308-9","article-title":"Oral teriflunomide for patients with relapsing multiple sclerosis (TOWER): a randomised, double-blind, placebo-controlled, phase 3 trial","volume":"13","author":"Confavreux","year":"2014","journal-title":"Lancet Neurol"},{"key":"R7-20250504","doi-asserted-by":"crossref","first-page":"920","DOI":"10.1212\/WNL.0000000000002441","article-title":"Long-term safety and efficacy of teriflunomide: nine-year follow-up of the randomized TEMSO study","volume":"86","author":"O\u2019Connor","year":"2016","journal-title":"Neurology"},{"key":"R8-20250504","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1016\/j.msard.2015.11.006","article-title":"Pooled safety and tolerability data from four placebo-controlled teriflunomide studies and extensions","volume":"5","author":"Comi","year":"2016","journal-title":"Mult Scler Relat Disord"},{"key":"R9-20250504","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1038\/clpt.1981.154","article-title":"A method for estimating the probability of adverse drug reactions","volume":"30","author":"Naranjo","year":"1981","journal-title":"Clin Pharmacol Ther"},{"key":"R10-20250504","doi-asserted-by":"crossref","first-page":"878","DOI":"10.14309\/ajg.0000000000001259","article-title":"ACG clinical guideline: diagnosis and management of idiosyncratic drug-induced liver injury","volume":"116","author":"Chalasani","year":"2021","journal-title":"Am J Gastroenterol"},{"key":"R11-20250504","doi-asserted-by":"crossref","first-page":"1633","DOI":"10.1177\/1352458518799598","article-title":"Liver injury with drugs used for multiple sclerosis: a contemporary analysis of the FDA Adverse Event Reporting System","volume":"25","author":"Antonazzo","year":"2019","journal-title":"Mult Scler J"},{"key":"R14-20250504","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/j.msard.2017.03.014","article-title":"Vitamin D and multiple sclerosis: an update","volume":"14","author":"Pierrot-Deseilligny","year":"2017","journal-title":"Mult Scler Relat Disord"},{"key":"R15-20250504","doi-asserted-by":"crossref","first-page":"1543","DOI":"10.1002\/pds.4792","article-title":"Safety of medicines\u2014pharmacists\u2019 knowledge, practice, and attitudes toward pharmacovigilance and adverse drug reactions reporting process","volume":"28","author":"Kopciuch","year":"2019","journal-title":"Pharmacoepidemiol Drug Saf"}],"container-title":["Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000028246","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,4]],"date-time":"2025-05-04T06:07:41Z","timestamp":1746338861000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000028246"}},"subtitle":["A case report"],"short-title":[],"issued":{"date-parts":[[2021,12,23]]},"references-count":11,"journal-issue":{"issue":"51","published-online":{"date-parts":[[2021]]}},"URL":"https:\/\/doi.org\/10.1097\/md.0000000000028246","relation":{},"ISSN":["0025-7974","1536-5964"],"issn-type":[{"type":"print","value":"0025-7974"},{"type":"electronic","value":"1536-5964"}],"subject":[],"published":{"date-parts":[[2021,12,23]]},"assertion":[{"value":"2021-10-29","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2021-11-25","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}